Erythrocyte Sedimentation Rate—A Predictor of Malignant Potential in Early Prostate Cancer

Authors

  • Michael Borre Danish Cancer Society, Departments of Experimental Clinical Oncology, Denmark; Urology, The University Hospital of Aarhus, Denmark
  • Benni Nerstrøm Urology, The University Hospital of Aarhus, Denmark
  • Jens Overgaard Danish Cancer Society, Departments of Experimental Clinical Oncology, Denmark

DOI:

https://doi.org/10.3109/02841869709001338

Abstract

The prognostic value of the erythrocyte sedimentation rate (ESR) was investigated in a population-based prostate cancer study, comparing 556 patients treated with no intent to cure. The data originated from hospital charts and death certificates. A statistically significant relationship between ESR at diagnosis and overall as well as disease-specific survival was demonstrated by univariate and multivariate analyses. A similar result was demonstrated in the 179 patients suffering from clinically organ-confined (T1-2,Nx,MO) disease. In a subpopulation consisting entirely of clinically organ-confined, small (T1), well-differentiated tumors, the dichotomized ESR (± 20 mm/h vs. > 20 mm/h) at the time of diagnosis distinguished between aggressive and non-aggressive tumors. In a small, second prostate cancer population it was demonstrated that ESR was not a surrogate marker for prostate- specific antigen (PSA). Our results indicate that ESR is a significant predictor of survival in early localized prostate cancer.

Downloads

Download data is not yet available.

Downloads

Published

1997-01-01

How to Cite

Borre, M. ., Nerstrøm, B. ., & Overgaard, J. . (1997). Erythrocyte Sedimentation Rate—A Predictor of Malignant Potential in Early Prostate Cancer. Acta Oncologica, 36(7), 689–694. https://doi.org/10.3109/02841869709001338